Literature DB >> 7240381

Radioimmunoassay for the middle region of human parathyroid hormone: studies with a radioiodinated synthetic peptide.

S J Marx, M E Sharp, A Krudy, M Rosenblatt, L E Mallette.   

Abstract

We radioiodinated a synthetic fragment representing residues 44-68 from the middle region of human parathyroid hormone (hPTH). At least 90% of the purified [125I]-hPTH-(44-68) was able to bind to anti-hPTH serum. Antibody-bound [125I]hPTH-(44-68) could be rapidly and efficiently separated from nonbound radioligand by dextran-coated charcoal. [125I]hPTH-(44-68) was not degraded after a 72-h incubation in undiluted plasma at 7 C, and it was stable for many weeks at -20 C in a 1% albumin buffer. [125I]hPTH-(44-68) was used to develop midregion specific PTH RIAs. The immunoreactive PTH concentration in plasma was above the upper limit of the normal range in 39 of 43 patients with primary hyperparathyroidism. Values from the midregion assay and an established carboxy-terminus assay correlated using peripheral plasma from 17 patients with primary hyperparathyroidism (r = 0.84; P less than 0.0001) or using parathyroid gland venous effluent plasma from the same 17 patients (r = 0.79; P less than 0.0005). Gel filtration analysis of peripheral plasma from 2 patients with primary hyperparathyroidism and azotemia suggested peptides possessing midregion immunoreactivity but deficient in carboxyterminus immunoreactivity. Similar peptides were present at higher concentrations in parathyroid gland venous effluent plasma than in peripheral plasma, indicating release from the parathyroid gland. In conclusion, [125I]hPTH-(44-68) had properties favorable for the development of RIAs reactive solely with the midregion of PTH. Fragments secreted in vivo by two human parathyroid glands were reactive in midregion assays but nonreactive in a carboxy-terminus assay.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240381     DOI: 10.1210/jcem-53-1-76

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Functional epithelial cell line cloned from rat parathyroid glands.

Authors:  K Sakaguchi; A Santora; M Zimering; F Curcio; G D Aurbach; M L Brandi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  Distribution and concentration of immunoreactive parathyroid hormone in brain and pituitary of sheep.

Authors:  S Balabanova; O King; W M Teller; G Reinhardt
Journal:  Klin Wochenschr       Date:  1985-05-02

3.  Bovine parathyroid cells: cultures maintained for more than 140 population doublings.

Authors:  M L Brandi; L A Fitzpatrick; H G Coon; G D Aurbach
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Persistent arthralgia, vomiting and hypercalcemia as the initial manifestations of hyperthyroidism: A case report.

Authors:  Jingfang Liu; Xulei Tang; Jianguo Cheng; Xiaomei Yang; Yan Wang
Journal:  Mol Clin Oncol       Date:  2017-01-10

5.  Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism.

Authors:  J A Heinsimer; A O Davies; R W Downs; M A Levine; A M Spiegel; M K Drezner; A De Lean; K A Wreggett; M G Caron; R J Lefkowitz
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

6.  Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism.

Authors:  M F Attie; J R Gill; J L Stock; A M Spiegel; R W Downs; M A Levine; S J Marx
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

7.  Factors that influence the assessment of parathyroid graft function.

Authors:  L E Mallette; K L Eisenberg; S D Schwaitzberg; G P Noon
Journal:  Ann Surg       Date:  1984-02       Impact factor: 12.969

8.  Conventional and new diagnostic applications of a two-site immunochemiluminometric assay for parathyroid hormone.

Authors:  S Minisola; L Scarnecchia; E Romagnoli; V Carnevale; M T Pacitti; A Scarda; R Rosso; G F Mazzuoli
Journal:  J Endocrinol Invest       Date:  1992 Jul-Aug       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.